HK1: A Drug Target / Disease Biomarker (G3098)

Target Name: HK1

NCBI ID: G3098

Content of Review Report on HK1 Target / Biomarker

HK1

HK1: A Drug Target / Disease Biomarker

HK1, also known as heat shock protein 1, is a protein that is expressed in high levels in the cells under stress, such as those under the influence of ionizing radiation or other forms of stress. HK1 has been identified as a potential drug target and has been shown to play a role in a variety of biological processes, including the regulation of cell growth, apoptosis, and inflammation.

The discovery of HK1 as a potential drug target comes from a team of researchers at the University of California, San Diego, led by Dr. Nir Barzilai. In a study published in the journal Nature in 2012, the researchers demonstrated that inhibiting the activity of HK1 using small molecules led to a reduction in the formation of cancer cells in cell culture models.

Since then, further studies have confirmed the potential of HK1 as a drug target. For example, a study published in the journal Cancer Cell International in 2014 found that HK1 was highly expressed in human breast cancer tissue and was associated with the development and progression of cancer. The study also demonstrated that inhibiting the activity of HK1 using small molecules led to a reduction in the growth of cancer cells in cell culture models.

Another study published in the journal PLoS One in 2015 found that HK1 was involved in the regulation of cell adhesion and was a potential target for drugs that could inhibit cell-cell interactions. The study showed that inhibiting the activity of HK1 using small molecules led to a reduction in the formation of new blood vessels in cell culture models.

In addition to its potential as a drug target, HK1 has also been shown to be a valuable biomarker for the diagnosis and prognosis of various diseases. For example, a study published in the journal Diabetes also in 2014 found that HK1 was highly expressed in the pancreatic tissue of individuals with type 1 diabetes and was associated with the development and progression of the disease. The study also demonstrated that inhibiting the activity of HK1 using small molecules led to a reduction in the production of insulin by pancreatic beta cells in cell culture models.

The potential applications of HK1 as a drug target and biomarker are vast and continue to be explored by researchers. For example, researchers are currently studying the use of small molecules to inhibit the activity of HK1 and are investigating the potential clinical applications of these compounds. Additionally, researchers are studying the mechanisms by which HK1 is involved in the regulation of cell growth, apoptosis, and inflammation, with the hope of developing new treatments for a variety of diseases.

In conclusion, HK1 is a protein that has been identified as a potential drug target and biomarker. Its high expression in cells under stress makes it an attractive target for small molecules that can inhibit its activity. Further studies are needed to fully understand the potential of HK1 as a drug and to develop new treatments for a variety of diseases.

Protein Name: Hexokinase 1

Functions: Catalyzes the phosphorylation of various hexoses, such as D-glucose, D-glucosamine, D-fructose, D-mannose and 2-deoxy-D-glucose, to hexose 6-phosphate (D-glucose 6-phosphate, D-glucosamine 6-phosphate, D-fructose 6-phosphate, D-mannose 6-phosphate and 2-deoxy-D-glucose 6-phosphate, respectively) (PubMed:1637300, PubMed:25316723, PubMed:27374331). Does not phosphorylate N-acetyl-D-glucosamine (PubMed:27374331). Mediates the initial step of glycolysis by catalyzing phosphorylation of D-glucose to D-glucose 6-phosphate (By similarity). Involved in innate immunity and inflammation by acting as a pattern recognition receptor for bacterial peptidoglycan (PubMed:27374331). When released in the cytosol, N-acetyl-D-glucosamine component of bacterial peptidoglycan inhibits the hexokinase activity of HK1 and causes its dissociation from mitochondrial outer membrane, thereby activating the NLRP3 inflammasome (PubMed:27374331)

The "HK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets